243 related articles for article (PubMed ID: 23626689)
21. Investigation of
Cevik M; Namal E; Sener ND; Koksal UI; Cagatay P; Deliorman G; Ciftci C; Karaalp A; Susleyici B
Per Med; 2022 Sep; 19(5):435-444. PubMed ID: 35880438
[TBL] [Abstract][Full Text] [Related]
22. [Polymorphism of methylenetetrahydrofolate reductase and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy].
Gao CM; Lu JW; Toshiro T; Wu JZ; Cao HX; Chen HQ; Feng JF; Kazuo T
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Dec; 25(12):1054-8. PubMed ID: 15769364
[TBL] [Abstract][Full Text] [Related]
23. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
24. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes.
Pardini B; Kumar R; Naccarati A; Novotny J; Prasad RB; Forsti A; Hemminki K; Vodicka P; Lorenzo Bermejo J
Br J Clin Pharmacol; 2011 Jul; 72(1):162-3. PubMed ID: 21204909
[No Abstract] [Full Text] [Related]
25. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
[TBL] [Abstract][Full Text] [Related]
26. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer.
Liu D; Wu J; Shi GY; Zhou HF; Yu Y
Genet Mol Res; 2014 Apr; 13(2):3100-7. PubMed ID: 24782167
[TBL] [Abstract][Full Text] [Related]
27. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
Cohen V; Panet-Raymond V; Sabbaghian N; Morin I; Batist G; Rozen R
Clin Cancer Res; 2003 May; 9(5):1611-5. PubMed ID: 12738713
[TBL] [Abstract][Full Text] [Related]
28. Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
Lai CY; Sung FC; Hsieh LL; Tang R; Chiou HY; Wu FY; Yeh CC
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S599-606. PubMed ID: 23800895
[TBL] [Abstract][Full Text] [Related]
29. Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China.
Kong J; Liu Z; Cai F; Xu X; LiuI J
Clinics (Sao Paulo); 2018 Dec; 73():e455. PubMed ID: 30517302
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in Korean patients with gastric cancer].
Lee J; Jeong CK; Hong SP; Chong SY; Oh D; Hwang SG; Ahn DH; Kim S; Han JH; Kim NK
Korean J Gastroenterol; 2005 Jul; 46(1):32-8. PubMed ID: 16030402
[TBL] [Abstract][Full Text] [Related]
31. MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.
Cecchin E; Perrone G; Nobili S; Polesel J; De Mattia E; Zanusso C; Petreni P; Lonardi S; Pella N; D'Andrea M; Errante D; Rizzolio F; Mazzei T; Landini I; Mini E; Toffoli G
Pharmacogenomics J; 2015 Jun; 15(3):219-25. PubMed ID: 25331073
[TBL] [Abstract][Full Text] [Related]
32. 5,10-methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer.
Eaton AM; Sandler R; Carethers JM; Millikan RC; Galanko J; Keku TO
Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):2023-9. PubMed ID: 16103455
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
Naghibalhossaini F; Shefaghat M; Mansouri A; Jaberi H; Tatar M; Eftekhar E
Acta Med Iran; 2017 Dec; 55(12):751-758. PubMed ID: 29373881
[TBL] [Abstract][Full Text] [Related]
34. MLH1 -93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer.
Raptis S; Mrkonjic M; Green RC; Pethe VV; Monga N; Chan YM; Daftary D; Dicks E; Younghusband BH; Parfrey PS; Gallinger SS; McLaughlin JR; Knight JA; Bapat B
J Natl Cancer Inst; 2007 Mar; 99(6):463-74. PubMed ID: 17374836
[TBL] [Abstract][Full Text] [Related]
35. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
[TBL] [Abstract][Full Text] [Related]
36. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer.
de Vogel S; Wouters KA; Gottschalk RW; van Schooten FJ; de Goeij AF; de Bruïne AP; Goldbohm RA; van den Brandt PA; Weijenberg MP; van Engeland M
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3086-96. PubMed ID: 19843671
[TBL] [Abstract][Full Text] [Related]
37. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in genes involved in folate metabolism and plasma DNA methylation in colorectal cancer patients.
Kim JW; Park HM; Choi YK; Chong SY; Oh D; Kim NK
Oncol Rep; 2011 Jan; 25(1):167-72. PubMed ID: 21109973
[TBL] [Abstract][Full Text] [Related]
39. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer.
Zhang W; Press OA; Haiman CA; Yang DY; Gordon MA; Fazzone W; El-Khoueiry A; Iqbal S; Sherrod AE; Lurje G; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3726-31. PubMed ID: 17704422
[TBL] [Abstract][Full Text] [Related]
40. Genetic Association between ERCC5 rs17655 Polymorphism and Colorectal Cancer Risk: Evidence Based on a Meta-analysis.
Zeng Y; Wei L; Wang YJ; Liu C
Asian Pac J Cancer Prev; 2015; 16(13):5565-71. PubMed ID: 26225711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
